Liver Cancer (Hepatocellular Carcinoma) clinical trials
Showing 151–188 of 188 active trials. Describe your situation to see which ones look like a fit.
- Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
- Targeted Navigation in Hepatocellular Carcinoma (HCC)
- Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
- Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
- THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
- Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
- Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
- GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
- Defining the Ablative Dose for Y-90 TARE
- Fibrinogen in Liver Transplant
- Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
- Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
- Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
- Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis
- LTFU for All Cell and Gene Therapy Studies
- Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
- Social Determinants of Health HCC Trial
- Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
- Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE
- FAST (Focused Abbreviated Screening Technique)-MRI Study
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Streamlined Resin Y90 Radiation Segmentectomy for Small HCC
- Getting To Implementation: Improving Cancer Screening for Veterans
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
- Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
- Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.
- A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
- A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
- Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
- 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- Optimizing Y90 Therapy for Radiation Lobectomy
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.